We then selected shRNA sequence with the most potent silencing efficiency (shCRT/a, hereafter short hairpin RNA targeting Calreticulin [shCRT]), to evaluate the effects of CRT down-regulation on the proliferative capacity of melanoma cells expressing a mutant B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 allele (Mel727) versus cells with wild-type BRAF (Mel525). Here, MARK2 is linked to melanoma.